You are here

Par Pharma Gets FDA Approval for Glipizide ER Tablets

Generic Version of Pfizer's Glucotrol XL (September 27)

Par Pharmaceutical Companies, Inc. has received final approval from the Food and Drug Administration (FDA) for its Abbreviated New Drug Application for glipizide 5 mg and 10 mg extended-release (ER) tablets.

Glipizide ER is the generic version of Pfizer’s Glucotrol XL and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ??Par has begun shipping 5 mg and 10 mg strengths of the product.

According to IMS Health data, annual US sales of the 5 mg and 10 mg strengths of glipizide ER are approximately $89 million. Glipizide extended-release tablets are contraindicated in patients with: a known hypersensitivity to glipizide or any excipients in the tablets; and Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.

[Source: Pharmabiz.com, September 27, 2013.]

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs